

# UnitedHealthcare Community Plan of New Jersey Medical Policy Update Bulletin Quick View: January 2026



A list of recently approved, revised, and/or retired Medical Policies and/or Medical Benefit Drug Policies is provided below for your reference. **For a comprehensive summary of the latest updates, refer to the [Medical Policy Update Bulletin: January 2026](#).**

## Take Note

### Implementation Delay: Remote Physiologic Monitoring (RPM)

The Medical Policy titled *Remote Physiologic Monitoring (RPM) (for New Jersey Only)* will not be effective on Jan. 1, 2026, as previously announced; implementation of the new policy has been postponed until further notice.

### Annual HCPCS Code Updates

Effective **Jan. 1, 2026**, all applicable Medical Benefit Drug Policies will be updated to reflect the 2026 Current Healthcare Common Procedure Coding System (HCPCS) code additions and deletions. Refer to the Centers for Medicare & Medicaid Services: Healthcare Common Procedure Coding System (HCPCS) Quarterly Update for information on the code updates. Refer to the Medical Policy Update Bulletin: January 2026 for a list of impacted policies and corresponding details.

## Medical Policy Updates

Policy Title	Status	Effective Date
Apheresis (for New Jersey Only)	Updated	Jan. 1, 2026
Electrical and Ultrasonic Bone Growth Stimulators (for New Jersey Only)	Revised	Feb. 1, 2026
Electrical Stimulation for Wounds (for New Jersey Only)	Retired	Jan. 1, 2026
FDA Cleared or Approved Companion Diagnostic Testing (for New Jersey Only)	Revised	Mar. 1, 2026
Interspinous Fusion and Decompression Devices (for New Jersey Only)	Updated	Jan. 1, 2026
Pharmacogenetic Panel Testing (for New Jersey Only)	Updated	Jan. 1, 2026
Total Artificial Disc Replacement for the Spine (for New Jersey Only)	Revised	Mar. 1, 2026
Vagus and External Trigeminal Nerve Stimulation (for New Jersey Only)	Updated	Jan. 1, 2026
Video Electroencephalographic (vEEG) Monitoring and Recording (for New Jersey Only)	Updated	Jan. 1, 2026

## Medical Benefit Drug Policy Updates

Policy Title	Status	Effective Date
Cimzia® (Certolizumab Pegol)	Revised	Feb. 1, 2026
Gazyva® (Obinutuzumab)	New	Feb. 1, 2026
Infliximab	Revised	Feb. 1, 2026
Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease	Revised	Feb. 1, 2026
Ocrevus® (Ocrelizumab) and Ocrevus Zunovo® (Ocrelizumab and Hyaluronidase-Ocsq)	Revised	Feb. 1, 2026

Policy Title	Status	Effective Date
Respiratory Interleukins (Cinqair®, Fasenra®, & Nucala®)	Revised	Feb. 1, 2026
Subcutaneous Implantable Naltrexone Pellets	Updated	Jan. 1, 2026
Tezspire® (Tezepelumab-Ekko)	Revised	Feb. 1, 2026

## General Information

The inclusion of a health service (e.g., test, drug, device, or procedure) in this bulletin indicates only that UnitedHealthcare is adopting a new policy and/or updated, revised, replaced, or retired an existing policy; it does not imply that UnitedHealthcare provides coverage for the health service. Note that most benefit plan documents exclude from benefit coverage health services identified as investigational or unproven/not medically necessary. Physicians and other health care professionals may not seek or collect payment from a member for services not covered by the applicable benefit plan unless first obtaining the member's written consent, acknowledging that the service is not covered by the benefit plan and that they will be billed directly for the service.

**Note:** The absence of a policy does not automatically indicate or imply coverage. As always, coverage for a health service must be determined in accordance with the member's benefit plan and any applicable federal or state regulatory requirements. Additionally, UnitedHealthcare reserves the right to review the clinical evidence supporting the safety and effectiveness of a medical technology prior to rendering a coverage determination.

UnitedHealthcare respects the expertise of the physicians, health care professionals, and their staff who participate in our network. Our goal is to support you and your patients in making the most informed decisions regarding the choice of quality and cost-effective care, and to support practice staff with a simple and predictable administrative experience. The Medical Policy Update Bulletin was developed to share important information regarding changes to our Community Plan of New Jersey Medical Policies and Medical Benefit Drug Policies. When information in this bulletin conflicts with applicable state and/or federal law, UnitedHealthcare follows such applicable federal and/or state law.

## Policy Update Classifications

### *New*

New clinical coverage criteria have been adopted for a health service (e.g., test, drug, device, or procedure)

### *Updated*

An existing policy has been reviewed and changes have not been made to the clinical coverage criteria; however, items such as the clinical evidence, FDA information, and/or list(s) of applicable codes may have been updated

### *Revised*

An existing policy has been reviewed and revisions have been made to the clinical coverage criteria

### *Replaced*

An existing policy has been replaced with a new or different policy

### *Retired*

The health service(s) addressed in the policy are no longer being managed or are considered to be proven/medically necessary and are therefore not excluded as unproven/not medically necessary services, unless coverage guidelines or criteria are otherwise documented in another policy



The complete library of UnitedHealthcare Community Plan of New Jersey Medical Policies and Medical Benefit Drug Policies is available at [UHCprovider.com/NJ](https://UHCprovider.com/NJ) > Community Plan (Medicaid) > Current Policies and Clinical Guidelines > [Medical & Drug Policies](#).